Market Research Logo

Fallopian Tube Cancer - Pipeline Review, H2 2015

Fallopian Tube Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Fallopian Tube Cancer - Pipeline Review, H2 2015’, provides an overview of the Fallopian Tube Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fallopian Tube Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fallopian Tube Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Fallopian Tube Cancer Overview
Therapeutics Development
Pipeline Products for Fallopian Tube Cancer - Overview
Pipeline Products for Fallopian Tube Cancer - Comparative Analysis
Fallopian Tube Cancer - Therapeutics under Development by Companies
Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes
Fallopian Tube Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fallopian Tube Cancer - Products under Development by Companies
Fallopian Tube Cancer - Products under Investigation by Universities/Institutes
Fallopian Tube Cancer - Companies Involved in Therapeutics Development
AbbVie Inc.
Acceleron Pharma, Inc.
Adaptimmune Limited
Amgen Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
Bayer AG
BioMarin Pharmaceutical Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Caladrius Biosciences, Inc.
Celldex Therapeutics, Inc.
Celsion Corporation
Cerulean Pharma, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Critical Outcome Technologies Inc.
CTI BioPharma Corp.
Curis, Inc.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Genentech, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Glycotope GmbH
Gradalis Inc.
Hetero Drugs Limited
Immune Design Corp.
ImmunoGen, Inc.
Immunotope, Inc.
Immunovaccine, Inc.
Incyte Corporation
Innate Pharma SA
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lee's Pharmaceutical Holdings Limited
MabVax Therapeutics Holdings, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Onxeo SA
Oxford BioMedica Plc
OXiGENE, Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
PsiOxus Therapeutics Limited
Recepta Biopharma S.A.
Sanofi Pasteur SA
Synta Pharmaceuticals Corp.
TapImmune Inc.
Tesaro, Inc.
TetraLogic Pharmaceuticals
Vascular Biogenics Ltd.
VentiRx Pharmaceuticals, Inc.
Fallopian Tube Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ID-LV305 + ID-G305) - Drug Profile
abexinostat hydrochloride - Drug Profile
abiraterone acetate - Drug Profile
ABT-767 - Drug Profile
afuresertib hydrochloride - Drug Profile
alisertib - Drug Profile
anetumab ravtansine - Drug Profile
AZD-1775 - Drug Profile
AZD-2014 - Drug Profile
AZD-5363 - Drug Profile
belinostat - Drug Profile
bevacizumab - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
binimetinib - Drug Profile
birinapant - Drug Profile
BNC-105 - Drug Profile
cabozantinib s-malate - Drug Profile
Cancer Stem Cell Therapy - Drug Profile
cancer vaccine - Drug Profile
CDX-1401 - Drug Profile
Cell Therapy for Target CD3 and HER2 for Oncology - Drug Profile
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile
Cell Therapy to Target WT1 for Cancer - Drug Profile
COTI-2 - Drug Profile
CRLX-101 - Drug Profile
CUDC-427 - Drug Profile
dalantercept - Drug Profile
demcizumab - Drug Profile
Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer - Drug Profile
DMUC-4064A - Drug Profile
DPX-Survivac - Drug Profile
EGEN-001 - Drug Profile
elesclomol - Drug Profile
enadenotucirev - Drug Profile
epacadostat - Drug Profile
erismodegib - Drug Profile
fosbretabulin tromethamine - Drug Profile
GALE-301 - Drug Profile
ganetespib - Drug Profile
Gene Therapy to Activate p53 for Oncology - Drug Profile
gimatecan - Drug Profile
guadecitabine - Drug Profile
IMT-1012 - Drug Profile
ipafricept - Drug Profile
IPH-2201 - Drug Profile
LCL-161 - Drug Profile
lifastuzumab vedotin - Drug Profile
lurbinectedin - Drug Profile
mifepristone - Drug Profile
mirvetuximab soravtansine - Drug Profile
MK-2206 - Drug Profile
motolimod - Drug Profile
nintedanib - Drug Profile
niraparib - Drug Profile
NSC-748933 - Drug Profile
OBI-822/821 - Drug Profile
olaratumab - Drug Profile
paclitaxel - Drug Profile
paclitaxel poliglumex - Drug Profile
PankoMab-GEX - Drug Profile
pazopanib hydrochloride - Drug Profile
pelareorep - Drug Profile
pembrolizumab - Drug Profile
prexasertib - Drug Profile
ralimetinib mesylate - Drug Profile
ramucirumab - Drug Profile
RebmAb-100 - Drug Profile
regorafenib - Drug Profile
rucaparib phosphate - Drug Profile
selinexor - Drug Profile
seribantumab - Drug Profile
talazoparib - Drug Profile
tivozanib - Drug Profile
TPIV-200 - Drug Profile
trabectedin - Drug Profile
trebananib - Drug Profile
tremelimumab - Drug Profile
TroVax - Drug Profile
Vaccine for Oncology - Drug Profile
varlilumab - Drug Profile
VB-111 - Drug Profile
vCP-2292 - Drug Profile
veliparib - Drug Profile
X-82 - Drug Profile
Fallopian Tube Cancer - Recent Pipeline Updates
Fallopian Tube Cancer - Dormant Projects
Fallopian Tube Cancer - Discontinued Products
Fallopian Tube Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Fallopian Tube Cancer, H2 2015
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015
Fallopian Tube Cancer - Pipeline by AbbVie Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Adaptimmune Limited, H2 2015
Fallopian Tube Cancer - Pipeline by Amgen Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Array BioPharma Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H2 2015
Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2015
Fallopian Tube Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Bionomics Limited, H2 2015
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Fallopian Tube Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Celsion Corporation, H2 2015
Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015
Fallopian Tube Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H2 2015
Fallopian Tube Cancer - Pipeline by Curis, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Fallopian Tube Cancer - Pipeline by EirGenix Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H2 2015
Fallopian Tube Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Genentech, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Fallopian Tube Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H2 2015
Fallopian Tube Cancer - Pipeline by Gradalis Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Hetero Drugs Limited, H2 2015
Fallopian Tube Cancer - Pipeline by Immune Design Corp., H2 2015
Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Immunotope, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Incyte Corporation, H2 2015
Fallopian Tube Cancer - Pipeline by Innate Pharma SA, H2 2015
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2015
Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H2 2015
Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2015
Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2015
Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Oncobiologics, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Onxeo SA, H2 2015
Fallopian Tube Cancer - Pipeline by Oxford BioMedica Plc, H2 2015
Fallopian Tube Cancer - Pipeline by OXiGENE, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Fallopian Tube Cancer - Pipeline by Pharmacyclics, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Fallopian Tube Cancer - Pipeline by Recepta Biopharma S.A., H2 2015
Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2015
Fallopian Tube Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Fallopian Tube Cancer - Pipeline by TapImmune Inc., H2 2015
Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H2 2015
Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Fallopian Tube Cancer - Pipeline by Vascular Biogenics Ltd., H2 2015
Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Fallopian Tube Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Fallopian Tube Cancer - Dormant Projects, H2 2015
Fallopian Tube Cancer - Dormant Projects (Contd..1), H2 2015
Fallopian Tube Cancer - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Fallopian Tube Cancer, H2 2015
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report